Possible companies we may be partnering with... ;
Post# of 153964
(Total Views: 422)
Posted On: 02/06/2020 6:39:12 PM
Possible companies we may be partnering with... 
Trying my hardest to determine which companies own 8 Tier 3 hospitals.. Very hard sorting through chinese data.. Much of it is very old.. And yes, I used Tier 3 because it was stated wrong on the call. Tier 1 are small. Tier 3 are over 1000 bed hospitals.
Innovative Cellular Therapeutics (ICT), Shanghai. ICT is combining stem cells, gene editing, gene therapy and CAR technologies to develop cancer treatments. They have one of the largest pipelines of cell therapies under development and some of the treatments closest to be approved in China and reach patients with blood cancers.
Cellular Biomedicine Group (CBMG), Shanghai, Beijing and Hong Kong. Founded in 2001, CBMG is already developing nine CAR-T therapies, some of them including additional improvements such as the ability to recognize multiple cancer markers or antigens. In 2015 they significantly increased their capabilities when they partner with the Chinese PLA General Hospital, one of the front runner CAR-T academic institutions in China. Additionally, they are also developing stem cell and cancer vaccine therapies.
CARsgen Therapeutics, Shanghai. Compared with CBMG, CARsgene may seem as a newcomer, only funded in October 2014. However, they partnered with the leading cancer research centers in Shanghai and licensed six CAR-T already in clinical development. Additionally, they are developing multiple innovations with their collaborators, such as logic-CAR to enable a better control of the immune response towards cancer cells.
PersonGen Biomedicine, Suzhou. In addition to develop CAR-T cell therapies, PersonGen is also working on CAR-NK, an approach that could enhance the patients’ innate immunity to fight cancer. They are pioneering this space with the most advanced CAR-NK therapies.
Hebei Senlang Biotech, Shijiazhuang. Hebei Senlang is developing therapies utilizing two mechanisms to direct the immune system towards cancer cells: CAR and TCR technologies. While CAR has shown the best results in blood cancers, TCR could be better suited for solid tumors. They already have eight therapies under development.
Trying my hardest to determine which companies own 8 Tier 3 hospitals.. Very hard sorting through chinese data.. Much of it is very old.. And yes, I used Tier 3 because it was stated wrong on the call. Tier 1 are small. Tier 3 are over 1000 bed hospitals. Innovative Cellular Therapeutics (ICT), Shanghai. ICT is combining stem cells, gene editing, gene therapy and CAR technologies to develop cancer treatments. They have one of the largest pipelines of cell therapies under development and some of the treatments closest to be approved in China and reach patients with blood cancers.
Cellular Biomedicine Group (CBMG), Shanghai, Beijing and Hong Kong. Founded in 2001, CBMG is already developing nine CAR-T therapies, some of them including additional improvements such as the ability to recognize multiple cancer markers or antigens. In 2015 they significantly increased their capabilities when they partner with the Chinese PLA General Hospital, one of the front runner CAR-T academic institutions in China. Additionally, they are also developing stem cell and cancer vaccine therapies.
CARsgen Therapeutics, Shanghai. Compared with CBMG, CARsgene may seem as a newcomer, only funded in October 2014. However, they partnered with the leading cancer research centers in Shanghai and licensed six CAR-T already in clinical development. Additionally, they are developing multiple innovations with their collaborators, such as logic-CAR to enable a better control of the immune response towards cancer cells.
PersonGen Biomedicine, Suzhou. In addition to develop CAR-T cell therapies, PersonGen is also working on CAR-NK, an approach that could enhance the patients’ innate immunity to fight cancer. They are pioneering this space with the most advanced CAR-NK therapies.
Hebei Senlang Biotech, Shijiazhuang. Hebei Senlang is developing therapies utilizing two mechanisms to direct the immune system towards cancer cells: CAR and TCR technologies. While CAR has shown the best results in blood cancers, TCR could be better suited for solid tumors. They already have eight therapies under development.
(2)
(0)